Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
View in:
PubMed
subject areas
Animals
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Cell Cycle Checkpoints
Cell Line, Tumor
Drug Synergism
Female
Humans
Leukocytes, Mononuclear
Mice
Mitogen-Activated Protein Kinase Kinases
Multiple Myeloma
Primary Cell Culture
Protein Kinase Inhibitors
Quinolones
Thiophenes
Xenograft Model Antitumor Assays
authors with profiles
Andrzej Jakubowiak
Yusuke Nakamura